Charles Explorer logo
🇬🇧

The importance of dual HER2 blockade in early HER2-positive breast cancer

Publication at First Faculty of Medicine |
2023

Abstract

Breast cancer with HER2 positivity accounts for about 15% of all diagnosed breast cancers. Overexpression and amplification of HER2 is associated with a worse prognosis however, it is also an effective target for anti-HER2 therapy.

Complete blockade of the HER2 receptor-mediated signal for tumour growth and progression is a bigger guarantee of the efficacy of anti-HER2 therapy at different stages of the disease.